In addition, the analyses reported reduced breast cancer-specific mortality in breast cancer-affected women carrying BRCA1/BRCA2 P/LP variants combined (RR 0.26; 95% CI 0.18–0.39) [141]. Here, BRCA2 is linked to breast carcinoma.